Mycotopia Therapies Signs Agreement With Havn Life Sciences For Purchase of Psilocybin SPP
25 août 2021 08h00 HE
|
Mycotopia Therapies Inc.
MIAMI, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Mycotopia Therapies, Inc. (OTC Pink: TPIA) (the “Company”), a company focused on psychedelic therapies, announced today it has entered into a Psilocybin...
Inotiv Acquires Laboratory Instrumentation for Discovery and Development of Novel Therapies
15 juil. 2021 08h33 HE
|
Inotiv, Inc.
WEST LAFAYETTE, Ind., July 15, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and...
Inotiv Acquires Genetic Toxicology Assets from MilliporeSigma’s BioReliance® portfolio
12 juil. 2021 08h33 HE
|
Inotiv, Inc.
WEST LAFAYETTE, Ind., July 12, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and...
Qualigen Therapeutics, Inc. to present at the Oppenheimer 31st Annual Healthcare Conference
08 mars 2021 08h30 HE
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and...
Interpace Biosciences Announces CFO Leadership Transition
04 févr. 2021 16h42 HE
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) (“Interpace”) a leader in enabling personalized medicine, announced today that its Board of Directors has...
CYBIN Closes Acquisition of Adelia Therapeutics; Bolsters Scientific Team and Grows IP Portfolio to 7 Patent Filings
14 déc. 2020 08h07 HE
|
Cybin Inc.
--Newly acquired novel psychedelic molecules diversify Cybin’s development portfolio, providing access to multiple future indications-- --Adelia brings a range of technologies related to novel...
Corbus Pharmaceuticals to Report Fourth Quarter and Year-End 2019 Results on March 12, 2020
05 mars 2020 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
- Management to host conference call and webcast on Thursday, March 12 at 8:30 a.m. ET - Norwood, MA, March 05, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP)...
Corbus Pharmaceuticals Completes Enrollment of Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis
18 nov. 2019 08h17 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Company expects to report topline data from study in the summer of 2020Primary endpoint of this study is reduction in pulmonary exacerbationsStudy enrolled participants regardless of CFTR mutation...
Corbus Pharmaceuticals Reports 2019 Second Quarter Financial Results and Provides Clinical and Corporate Updates
08 août 2019 07h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Clinical development of lenabasum on target for 2020 data readouts in lead indications systemic sclerosis and cystic fibrosis; diseases affect ~270,000 people total in U.S., EU and Japan CRB-4001 on...
Corbus Pharmaceuticals to Present at the Oppenheimer 29th Annual Healthcare Conference
11 mars 2019 08h35 HE
|
Corbus Pharmaceuticals Holdings, Inc.
- Presentation with live audio webcast on Tuesday, March 19, 2019 at 2:10 p.m. ET- Norwood, MA, March 11, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or...